跳到正文
BioPharm International·· 12 天前AI 评分39

阿斯利康收购Omniose,纳入生物偶联疫苗平台

AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform

AI 导读

阿斯利康于11月10日宣布收购临床前生物技术公司Omniose,将其单细胞大肠杆菌生物偶联平台纳入传染病事业部,Omniose成为全资子公司。双方自2024年起已有三年独家研究合作,交易财务条款、目标病原体及开发时间表均未披露。所涉疫苗项目仍处临床前阶段,公告未提供安全性、免疫原性或生产工艺数据。

正文 · 原文

AstraZeneca acquired preclinical biotech Omniose, adding a bioconjugation platform for conjugate vaccines against serious bacterial infections.

AstraZeneca has acquired Omniose, a preclinical biotechnology company, adding a bioconjugation platform for conjugate vaccines to its infectious disease portfolio, Omniose announced Nov. 10.1 Omniose becomes a wholly owned subsidiary and part of AstraZeneca’s Infectious Disease Unit, following a three-year exclusive research collaboration between the two.1

The transaction puts a manufacturing question at the center of vaccine strategy: whether assembling an antigen and its carrier protein inside one engineered cell can simplify a process that has traditionally relied on multiple chemical steps.

Benjamin Moutier, senior vice president, infectious disease at AstraZeneca, said: “Omniose’s bioconjugation platform represents a differentiated approach to engineering conjugate vaccines and strengthens our ability to develop novel vaccines against serious bacterial infections. Building on the strong scientific collaboration between our teams, we look forward to advancing these programs and realizing the potential of this technology for patients.”1

Key Facts

  • Deal: AstraZeneca acquires Omniose, announced Nov. 10
  • Structure: Wholly owned subsidiary of AstraZeneca
  • Unit: AstraZeneca Infectious Disease Unit
  • Platform: Single-cell E. coli bioconjugation
  • Stage: Preclinical vaccine programs
  • Background: 3-year exclusive collaboration since 2024
  • Financial terms: Not disclosed
“The acquisition by AstraZeneca is a great outcome for both organizations. We share a vision for bringing the best science and talent together to address serious bacterial infections, which are increasingly complicated by antimicrobial resistance.”

Timothy Cooke, chief executive officer, Omniose1

What did AstraZeneca acquire in the Omniose deal?

Omniose is an early-stage company developing polysaccharide conjugate vaccines against serious bacterial threats.1 The transaction adds its proprietary bioconjugation platform and related expertise to AstraZeneca’s preclinical vaccine programs.1

The announcement did not disclose financial terms, target pathogens or development timelines.

What did the earlier AstraZeneca–Omniose collaboration cover?

The companies signed the exclusive agreement in January 2024, giving AstraZeneca rights to the platform for up to three years to research vaccines against bacterial pathogens in its early vaccines and immune therapies pipeline.2 At the time, Omniose said earlier bioconjugation enzymes could address only a limited range of bacterial targets and that its approach expands that scope.2

That assessment comes from the company, and the acquisition announcement includes no supporting data. Christian Harding, chief scientific officer and co-founder of Omniose, said: “This milestone reflects the work of exceptional and complementary teams. AstraZeneca has been a trusted partner for several years, and this acquisition gives our platform the best chance to reach the patients it was built to serve.”1

How does bioconjugation differ from chemical conjugation?

Antibiotic-resistant bacterial infections are a growing public health threat, and glycoconjugate vaccines are among the most effective tools against bacterial disease, according to a 2019 review.3 These vaccines link a bacterial polysaccharide to a carrier protein, a pairing that supports durable immune memory.

Licensed products have historically covered a narrow set of pathogens, including Haemophilus influenzae type b, Neisseria meningitidis and some Streptococcus pneumoniae strains.3 Conventional manufacture requires purifying the polysaccharide from the pathogen, purifying and activating the carrier protein, chemically joining the two and purifying the product again.

Reviewers describe this multistep process as costly and prone to batch-to-batch variation.3 Omniose’s approach instead has a single E. coli cell produce the polysaccharide antigen, an engineered carrier protein and a conjugating enzyme that links them.1

Researchers in the field describe bioconjugation as a lower-cost, more flexible alternative to chemical conjugation, and several bioconjugate vaccines are in clinical trials.4

What remains unresolved after the acquisition?

The programs involved are preclinical, so the announcement offers no clinical safety or immunogenicity data for candidates built on the platform. It also provides no yield, purity, or cost figures that would show whether in-cell conjugation delivers the manufacturing advantages attributed to the approach.

Omniose has said its platform can attach virtually any bacterial polysaccharide antigen to engineered carrier proteins, a claim the announcement does not support with published data.1 Technical constraints in the field are documented.

The 2019 review noted that the coupling enzyme most widely used in bioconjugation is incompatible with most pneumococcal capsular serotypes, and that expressing diverse polysaccharides in E. coli can place a metabolic burden on the host cell, though newer enzymes have broadened the range of glycans that can be transferred.3 A 2025 review describes the technology’s promise of low-cost, custom-designed vaccines alongside its continued development.4

Next steps will depend on disclosures AstraZeneca has not yet made: which pathogens the programs will prioritize, when candidates might approach clinical testing and whether the single-cell process holds up at manufacturing scale.

Sources

1. Omniose announces its acquisition by AstraZeneca. News release. Business Wire. November 10, 2026. Accessed November 10, 2026. https://www.businesswire.com/news/home/20261110984674/en/Omniose-Announces-Its-Acquisition-by-AstraZeneca

2. Omniose announces scientific collaboration with AstraZeneca to research vaccines for serious bacterial diseases. News release. Business Wire. January 5, 2024. Accessed November 10, 2026. https://www.businesswire.com/news/home/20240105555701/en/Omniose-Announces-Scientific-Collaboration-With-AstraZeneca-to-Research-Vaccines-for-Serious-Bacterial-Diseases

3. Kay E, Cuccui J, Wren BW. Recent advances in the production of recombinant glycoconjugate vaccines. npj Vaccines. 2019;4:16. doi:10.1038/s41541-019-0110-z

4. Wren BW, Hall CL, Terra VS, et al. Recent advances in bioconjugate vaccine development. Vaccines (Basel). 2025;13(7):703. doi:10.3390/vaccines13070703

Related to this article

Efinopegdutide, an investigational GLP-1/glucagon co-agonist, met its 52-week MASH resolution endpoint in a phase 2b trial of 381 treated adults. Credit: Stock.Adobe.com/Formatoriginal

November 10th, 2026

Merck's GLP-1/glucagon co-agonist raised MASH resolution versus placebo at 52 weeks, but fibrosis and dose-response questions remain.

Read more

Weight loss pills available: Two dosing pens for subcutaneous injection of antidiabetic medication or anti-obesity medication on a blue background besides a heap of GLP-1 pills. | Image Credit: © Andreas Prott - © Andreas Prott - stock.adobe.com

November 9th, 2026

argenx's acquisition of Unnatural Products adds macrocyclic peptides that could yield oral or long-acting treatments for immune-mediated diseases.

Read more

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide

November 10th, 2026

FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.

Read more

FAQ: Sterility Assurance for Injectable Biologics

November 10th, 2026

This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.

Read more

3D illustration of a translucent blue human figure, seen from behind with arms outstretched, with the brain, spinal cord, and nerves in the arms highlighted in glowing orange and the rib cage visible. | Image Credit: © magicmine - stock.adobe.com

November 10th, 2026

Larimar Therapeutics has completed its rolling BLA for nomlabofusp, a frataxin replacement fusion protein, seeking accelerated approval based on skin frataxin as a novel surrogate endpoint. The company expects a potential US approval in mid-2027.

Read more

3D illustration of a translucent blue human upper torso showing a network of red lymphatic vessels and nodes, with several lymph nodes near the armpit highlighted in glowing yellow and the diaphragm visible at the bottom. | Image Credit: © jitendra jadhav - stock.adobe.com

November 10th, 2026

FDA granted RMAT and Fast Track designations to AbelZeta’s anti-CD20/CD19 CAR-T therapy prizlon-cel for relapsed or refractory large B-cell lymphoma. The company plans US studies after prior CAR-T therapy and in the second-line setting.

Read more

The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers

November 9th, 2026

argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.

Read more

Close-up of a hand pressing a white autoinjector pen with a red tip against a person’s upper arm. | Image Credit: © LaMorenita

November 9th, 2026

More monoclonal antibodies are moving from IV infusion to subcutaneous injection, but dose, volume, and viscosity still limit the switch. This FAQ covers the formulation science, the enabling technologies, what regulators require, and what remains unresolved.

Read more

来源:BioPharm International · biopharminternational.com